|
|
|
Market Research Report
Immunotherapies and Vaccines for Cancer and Infectious Diseases Report
|
Immunotherapies and Vaccines for Cancer and Infectious Diseases Report published by Insight Pharma Reports in October, 2008. This report consists of 390 pages and the price starts from US $ 3195.
Abstract
Overview
The field of therapeutic vaccines and immunotherapies is rapidly emerging as a
promising area. Use of passive immunotherapy (i.e., antibody) products, for
prevention of infection or for treatment of many diseases, including cancer,
is widespread. In addition, some nonspecific immunomodulators on the market
are used to treat certain cancers. However, there is considerable interest in
the development of novel, active specific immunotherapies and therapeutic
vaccines for cancer. No active specific immunotherapy products have yet
reached the market in the United States, but we may be getting close. Progress
is also being made in the development of therapeutic vaccines and
immunotherapies for treatment of chronic infectious diseases.
Immunotherapies and Vaccines for Cancer and Infectious Diseases reviews
current pharmacological options for 12 major cancers being targeted by
companies developing cancer immunotherapies or vaccines. While a large number
of drugs are available for these particular cancers, poor survival rates
demonstrate there is a clear need for more effective treatments. We then
include a discussion of currently available immunotherapies for chronic
infections, and infectious disease vaccines that are on the market.
We consider strategies companies are using to develop cancer immunotherapies
and vaccines, as well as different types of infectious disease vaccines, and
highlight the R&D challenges for these sectors. A large number of smaller
biopharmaceutical companies, and a more limited number of major pharmaceutical
companies, are developing a wide range of different approaches to stimulate
the immune system.
The many different product candidates that are in development for the 12
cancers targeted in this report are reviewed. In addition, we briefly touch
upon the numerous vaccines and immunotherapies that are in development for
other cancers.
In our section on infectious disease, we discuss novel prophylactic vaccines
that are in development for prevention of a wide range of different diseases.
We then focus on therapeutic vaccines and immunotherapies being developed for
treatment of chronic infections.
Immunotherapies and Vaccines for Cancer and Infectious Diseases
examines a number of business considerations and trends in the fields of
infectious disease and cancer immunotherapies and vaccines. Interviews with
nine experts in this area are provided, giving their perspectives on the
progress being made, and the challenges and hurdles faced by researchers and
companies working in this emerging field.
Table of Contents
Chapter - 1
- INTRODUCTION
- 1.1. The Immune System
- 1.2. Scope of This Report
Chapter - 2
- MAJOR CANCERS AND INFECTIOUS DISEASES TARGETED BY NEW AND/OR EMERGING
IMMUNOTHERAPIES AND VACCINES TO ENHANCE THE IMMUNE SYSTEM
- 2.1. Major Cancers Targeted by Immunotherapies and Vaccines
- Brain Cancer
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Leukemia
- Lung Cancer
- Non - Small-Cell Lung Cancer
- Small-Cell Lung Cancer
- Lymphoma (Non - Hodgkin' s Lymphoma)
- Melanoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Cancer
- 2.2. Major Infectious Diseases Targeted by Emerging Immunotherapies and
Vaccines
- Anthrax
- Campylobacter
- Cytomegalovirus
- Dengue
- Diphtheria
- Encephalitis
- Haemophilus influenzae Type b
- Hepatitis B Virus
- Hepatitis C Virus
- Herpes Simplex Virus
- Human Immunodeficiency Virus
- Human Papillomavirus
- Influenza
- Malaria
- Meningococcal Disease; Neisseria meningitidis
- Pertussis
- Pneumococcal Disease; Streptococcus pneumoniae
- Polio (Poliomyelitis)
- Respiratory Syncytial Virus
- Tetanus
- Tuberculosis
- West Nile Virus
Chapter - 3
- CURRENT PHARMACOLOGICAL OPTIONS FOR TREATMENT AND PREVENTION OF CANCER,
AND IMMUNOTHERAPY/VACCINE OPTIONS FOR TREATMENT AND PREVENTION OF INFECTIOUS
DISEASES
- 3.1. Current Pharmacological Options for Treatment and Prevention of
Cancer
- Brain Cancer
- Breast Cancer
- Chemotherapy
- Hormone Therapy
- Targeted Therapy: HER2-Positive Cancers
- Targeted Therapy: VEGF and Angiogenesis
- Cervical Cancer
- Colorectal Cancer
- Chemotherapy
- Targeted Therapy: Monoclonal Antibodies
- Leukemia
- Pharmacological Therapies (Chemotherapy and Others)
- Bone Marrow Transplants and Peripheral Stem Cell Transplants
- Lung Cancer
- Chemotherapy (Non - Small-Cell Lung Cancer)
- Targeted Therapy: Kinase Inhibitors (Non - Small-Cell Lung Cancer)
- Targeted Therapy: Monoclonal Antibodies (Non - Small-Cell Lung Cancer)
- Photodynamic Therapy (Non - Small-Cell Lung Cancer)
- Chemotherapy (Small-Cell Lung Cancer)
- Lymphoma (Non - Hodgkin' s Lymphoma)
- Chemotherapy
- Monoclonal Antibodies
- Other Immune-Based Therapies
- Other Targeted Therapies: Histone Deacetylase Inhibitor
- Melanoma
- Interferon
- Interleukin-2
- Chemotherapy
- Ovarian Cancer
- Pancreatic Cancer
- Chemotherapy
- Targeted Therapy: Inhibition of EGFR Tyrosine Kinase
- Prostate Cancer
- Luteinizing Hormone - Releasing Hormone Agonists
- Antiandrogens
- Chemotherapy
- Renal Cancer
- Targeted Therapy: Kinase Inhibitors
- 3.2. Current Infectious Disease Immunotherapies and Vaccines
- Passive Immunotherapy
- Immunotherapy for Treatment of Chronic Infections
- Infectious Disease Vaccines
- 3.3. Medical and Market Needs; R&D Challenges
- Cancer Immunotherapies and Vaccines
- Infectious Disease Immunotherapies and Vaccines
Chapter - 4
- EXAMPLES OF CURRENT AND EMERGING APPROACHES TO ENHANCE THE IMMUNE
SYSTEM FOR PREVENTION AND TREATMENT OF DISEASE
- 4.1. New Approaches for Cancer Immunotherapy and Vaccines
- Nonspecific Active Immunotherapy (Immune-Modulating Agents)
- Antigen Immunotherapies/Vaccines (Allogeneic)
- Autologous Antigen Immunotherapies/Vaccines
- Allogeneic Whole-Tumor-Cell Immunotherapies/Vaccines
- Autologous Whole-Tumor-Cell Immunotherapies/Vaccines
- Dendritic Cell Immunotherapies/Vaccines
- DNA and Viral Vector Vaccines
- 4.2. Infectious Disease Vaccines
- Types of Vaccines
- Adjuvants
Chapter - 5
- CANCER IMMUNOTHERAPIES AND VACCINES IN DEVELOPMENT
- 5.1. Brain Cancer
- Advantagene
- Antisense Pharma
- Celldex Therapeutics
- Merck Serono
- Northwest Biotherapeutics
- 5.2. Breast Cancer
- Antigen Express (Subsidiary of Generex Biotechnology)
- Apthera
- Celldex Therapeutics
- Introgen Therapeutics
- Peregrine Pharmaceuticals
- 5.3. Cervical Cancer
- 5.4. Colorectal Cancer
- Celldex Therapeutics
- GenVec
- immatics biotechnologies
- Oxford BioMedica and sanofi-aventis
- Vaccinogen
- 5.5. Leukemia
- Argos Therapeutics
- Cell Genesys
- Geron
- The Vaccine Company
- 5.6. Lung Cancer
- Agennix
- AVAX Technologies
- GlaxoSmithKline
- GlobeImmune
- IDM Pharma
- Introgen Therapeutics
- Merck Serono and Oncothyreon
- Merck Serono
- NovaRx
- Peregrine Pharmaceuticals
- Pfizer
- Pharmexa
- Transgene
- Vaxon Biotech
- 5.7. Lymphoma (Non - Hodgkin' s Lymphoma)
- Biovest International
- Transgene
- 5.8. Melanoma
- Antigenics
- AVAX Technologies
- BioVex
- GenVec
- GlaxoSmithKline
- Medarex and Bristol-Myers Squibb
- Merck Serono
- Oxford BioMedica
- Sanofi Pasteur
- SciClone Pharmaceuticals and Sigma-Tau
- Vical
- ZymoGenetics
- 5.9. Ovarian Cancer
- AVAX Technologies
- Menarini Group
- 5.10. Pancreatic Cancer
- Celldex Therapeutics
- Cell Genesys
- GenVec
- GlobeImmune
- Lorus Therapeutics and Zor Pharmaceuticals
- Pharmexa
- 5.11. Prostate Cancer
- Advantagene
- Bavarian Nordic
- Cell Genesys
- Dendreon
- Northwest Biotherapeutics
- Onyvax
- Oxford BioMedica and sanofi-aventis
- 5.12. Renal Cancer
- Active Biotech
- Agennix
- Antigenics
- Argos Therapeutics
- Endocyte
- Idera Pharmaceuticals and Merck Serono
- immatics biotechnologies
- LipoNova
- Oxford BioMedica and sanofi-aventis
- ZymoGenetics
- 5.13. Immunotherapies and Vaccines in Development for Other or
Nonspecified Cancer Indications
Chapter - 6
- IMMUNOTHERAPIES AND VACCINES IN DEVELOPMENT FOR PREVENTION AND
TREATMENT OF INFECTIOUS DISEASES
- 6.1. Anthrax and Other Biodefense Vaccines
- 6.2. Campylobacter and/or Enterotoxigenic Escherichia coli (Traveler' s
Diarrhea)
- Ace Biosciences
- Intercell
- 6.3. Cytomegalovirus
- 6.4. Dengue
- GlaxoSmith Kline
- Sanofi Pasteur
- 6.5. Encephalitis
- Novartis and Intercell
- Sanofi Pasteur
- 6.6. Hepatitis B
- Emergent BioSolutions
- Merck and Dynavax
- 6.7. Hepatitis C
- GlobeImmune
- Hemispherx Biopharma
- Human Genome Sciences and Novartis
- Novartis Vaccines and Intercell
- SciClone Pharmaceuticals
- 6.8. Herpes Simplex Virus
- 6.9. Human Immunodeficiency Virus (HIV)
- Argos Therapeutics
- Bionor Immuno
- GenVec
- Hemispherx Biopharma
- Sanofi Pasteur
- Targeted Genetics
- 6.10. Human Papillomavirus (HPV)
- GlaxoSmithKline
- Merck
- MGI Pharma (Subsidiary of Eisai)
- Transgene and Roche
- 6.11. Influenza
- Baxter Vaccines
- CSL Biotherapies
- GlaxoSmithKline
- Novartis Vaccines
- Protein Sciences Corporation
- Sanofi Pasteur
- 6.12. Malaria
- 6.13. Meningococcal Disease; Neisseria meningitidis
- 6.14. Pneumococcal Disease; Streptococcus pneumoniae
- 6.15. Respiratory Syncytial Virus
- 6.16. Tuberculosis
- Emergent BioSolutions
- GlaxoSmithKline
- 6.17. West Nile Virus
- 6.18. Emerging Combination Vaccines
- 6.19. Other Emerging Infectious Disease Vaccines
Chapter - 7
- SELECTED BUSINESS CONSIDERATIONS: IMMUNOTHERAPIES AND VACCINES THAT
ENHANCE THE IMMUNE SYSTEM
- 7.1. Companies in the Infectious Disease and Cancer Vaccines and
Immunotherapies Fields
- 7.2. Diseases Targeted for Product Development
- Infectious Disease
- Cancer
- 7.3. Technical Issues and Challenges for Cancer and Infectious Disease
Vaccines and Immunotherapies
- 7.4. Partners (Corporate and Noncorporate) and Acquisitions
- 7.5. Human Papillomavirus - Infectious Disease Prophylactic Vaccine for
Prevention of Cancer: Example of a Controversy with a New Vaccine
- Social Issues
- Safety Issues
Chapter - 8
- EXPERT INTERVIEWS
- Estuardo Aguilar-Cordova, MD, Founder & Chief Executive Officer,
Advantagene, Inc., Waban, MA
- David Apelian, MD, PhD, MBA, Vice President, Clinical Development
and Regulatory Affairs, and Chief Medical Officer, GlobeImmune, Louisville, CO
- Robert Coffin, PhD, Chief Technology Officer, Founder and Director,
BioVex, Woburn, MA
- Raafat E.F. Fahim, PhD, President and Chief Executive Officer, Nabi
Pharmaceuticals, Rockville, MD
- Drew Hannaman, Vice President, Research and Development, Ichor
Medical Systems, San Diego, CA
- Kristen M. Hege, MD, Vice President, Clinical Research and
Development, Cell Genesys, South San Francisco, CA
- Frank Malinoski, MD, PhD, Senior Vice President, Medical and
Scientific Affairs, MedImmune, Gaithersburg, MD
- Cynthia W. Tuthill, PhD, Senior Vice President, Scientific Affairs,
& Chief Scientific Officer, SciClone Pharmaceuticals, Foster City, CA
- Sunny Uberoi, Vice President, Corporate Communications, Antigenics,
New York, NY
References
Company Index with Web Addresses
|
 |
